Tumor response and clinical outcome in metastatic gastrointestinal stromal tumors under sunitinib therapy: Comparison of RECIST, Choi and volumetric criteria

European Journal of Radiology

Volumn 82, Issue 6, 2013, Pages 951-958

  Schramm, N ^a   Englhart, E ^a   Schlemmer, M ^a   Hittinger, M ^a   Ubleis C ^a   Becker, C R ^a   Reiser, M F ^a   Berger, F ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Choi criteria; Computed tomography; GIST; RECIST; Tumor response assessment

Indexed keywords

IMATINIB; SUNITINIB;

ABDOMEN; ADULT; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SPECIFIC SURVIVAL; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MALE; METASTATIC GASTROINTESTINAL STROMAL TUMOR; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT RESPONSE; VOLUMETRY;

ADOLESCENT; ADULT; ALGORITHMS; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMAGING, THREE-DIMENSIONAL; INDOLES; LIVER NEOPLASMS; MALE; MIDDLE AGED; PERITONEAL NEOPLASMS; PYRROLES; RADIOGRAPHIC IMAGE INTERPRETATION, COMPUTER-ASSISTED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR BURDEN; YOUNG ADULT;

EID: 84876905008     PISSN: 0720048X     EISSN: 18727727     Source Type: Journal    
DOI: 10.1016/j.ejrad.2013.02.034     Document Type: Article

References (28)

1. B. Liegl-Atzwanger, J.A. Fletcher, and C.D. Fletcher Gastrointestinal stromal tumors Virchows Archiv 456 2 2010 111 127
2. H. Joensuu, P.J. Roberts, and M. Sarlomo-Rikala Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor New England Journal of Medicine 344 14 2001 1052 1056
3. C. Le Tourneau, E. Raymond, and S. Faivre Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST) Ther Clin Risk Manag 3 2 2007 341 348
4. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada Journal of the National Cancer Institute 92 3 2000 205 216
5. E.A. Eisenhauer, P. Therasse, and J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) European Journal of Cancer 45 2 2009 228 247
6. H. Choi, C. Charnsangavej, and S. de Castro Faria CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings American Journal of Roentgenology 183 6 2004 1619 1628
7. H. Choi, C. Charnsangavej, and S.C. Faria Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria Journal of Clinical Oncology 25 13 2007 1753 1759
8. R.S. Benjamin, H. Choi, and H.A. Macapinlac We should desist using RECIST, at least in GIST Journal of Clinical Oncology 25 13 2007 1760 1764
9. A. Graser, C.R. Becker, M.F. Reiser, C. Stief, and M. Staehler Volumetry of metastases from renal cell carcinoma: comparison with the RECIST criteria Radiologe 48 9 2008 850 856
10. M. Montemurro, P. Schoffski, and P. Reichardt Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib European Journal of Cancer 45 13 2009 2293 2297
11. A.D. Van den Abbeele The lessons of GIST-PET and PET/CT: a new paradigm for imaging Oncologist 13 Suppl. 2 2008 8 13
12. G. Antoch, J. Kanja, and S. Bauer Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors Journal of Nuclear Medicine 45 3 2004 357 365
13. C.P. Heussel, S. Meier, S. Wittelsberger, H. Gotte, P. Mildenberger, and H.U. Kauczor Follow-up CT, measurement of liver malignoma according to RECIST and WHO vs. volumetry Rofo 179 9 2007 958 964
14. J.P. O'Connor, A. Jackson, M.C. Asselin, D.L. Buckley, G.J. Parker, and G.C. Jayson Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives Lancet Oncology 9 8 2008 766 776
15. S.C. Partridge, J.E. Gibbs, and Y. Lu MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival American Journal of Roentgenology 184 6 2005 1774 1781
16. M.F. Dempsey, B.R. Condon, and D.M. Hadley Measurement of tumor "size" in recurrent malignant glioma: 1D, 2D, or 3D? American Journal of Neuroradiology 26 4 2005 770 776
17. S. Shankar, E. vanSonnenberg, J. Desai, P.J. Dipiro, A. Van Den Abbeele, and G.D. Demetri Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate Radiology 235 3 2005 892 898
18. S. Faivre, G. Demetri, W. Sargent, and E. Raymond Molecular basis for sunitinib efficacy and future clinical development Nature Reviews Drug Discovery 6 9 2007 734 745
19. T. Jin, H. Nakatani, and T. Taguchi STI571 (Glivec) suppresses the expression of vascular endothelial growth factor in the gastrointestinal stromal tumor cell line, GIST-T1 World Journal of Gastroenterology 12 5 2006 703 708
20. H. Choi Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model Current Oncology Reports 7 4 2005 307 311
21. C.S. Wong, N. Gong, and Y.C. Chu Correlation of measurements from diffusion weighted MR imaging and FDG PET/CT in GIST patients: ADC versus SUV European Journal of Radiology 81 9 2012 2122 2126
22. M.J. Ratain, T. Eisen, and W.M. Stadler Phase II, placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma Journal of Clinical Oncology 24 16 2006 2505 2512
23. A.D. Smith, S.N. Shah, B.I. Rini, M.L. Lieber, and E.M. Remer Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy American Journal of Roentgenology 194 6 2010 1470 1478
24. A.A. van der Veldt, M.R. Meijerink, A.J. van den Eertwegh, J.B. Haanen, and E. Boven Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib British Journal of Cancer 102 5 2010 803 809
25. S. Stacchiotti, P. Collini, and A. Messina High-grade soft-tissue sarcomas: tumor response assessment - pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria Radiology 251 2 2009 447 456
26. O. Dudeck, M. Zeile, P. Reichardt, and D. Pink Comparison of RECIST and Choi criteria for computed tomographic response evaluation in patients with advanced gastrointestinal stromal tumor treated with sunitinib Annals of Oncology: Official Journal of the European Society for Medical Oncology 22 8 2011 1828 1833
27. M. Hittinger, M. Staehler, and N. Schramm Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy Urologic Oncology. 30 5 2011 695 703
28. N.J. Gong, C.S. Wong, Y.C. Chu, and J. Gu Treatment response monitoring in patients with gastrointestinal stromal tumor using diffusion-weighted imaging: preliminary results in comparison with positron emission tomography/computed tomography NMR in Biomedicine 26 2 2013 185 192